retatrutide phase 2 trial duration weight loss just delivered one of the largest weight-loss signals we've ever seen in a medication trial. In a study: • Up to 24.2% mean at 48 weeks Retatrutide Results: 24% Weight Loss

Employment status also influences treatment adherence, as research shows employed individuals demonstrate higher completion rates

10.1530/REP-10-0337 110

GLP-1 weight loss treatment is generally appropriate for adults with a BMI of 30 or higher, or 27 or higher with weight-related comorbidities such as type 2 diabetes, hypertension, or cardiovascular disease

Phase II then conjugates these modified toxins with other molecules, making them even more soluble and ready for excretion

Hosono, A., Tanabe, T., & Otani, H

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma